United Therapeutics (FRA:UTH) Cyclically Adjusted Revenue per Share: €43.65 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:UTH United Therapeutics Corp FRA:UTH
82 GF Score
Price €462.10
GF Value €334.33
Valuation Significantly Overvalued
! 3 Warning Signs
View Full Analysis

What is United Therapeutics Cyclically Adjusted Revenue per Share?

United Therapeutics FRA:UTH +1.03% 82 Cyclically Adjusted Revenue per Share is €43.65 as of Mar. 2026. GuruFocus rates FRA:UTH with a GF Score™ of 82/100 and a GF Value™ of €334.33 (Significantly Overvalued). The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

United Therapeutics's adjusted revenue per share for the three months ended in Mar. 2026 was €14.322. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €43.65 for the trailing ten years ended in Mar. 2026.

During the past 12 months, United Therapeutics's average Cyclically Adjusted Revenue Growth Rate was 8.80% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 8.80% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 10.20% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was 12.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of United Therapeutics was 35.70% per year. The lowest was 8.80% per year. And the median was 20.50% per year.

As of today (2026-07-27), United Therapeutics's current stock price is €462.10. United Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €43.65. United Therapeutics's Cyclically Adjusted PS Ratio of today is 10.59.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of United Therapeutics was 11.59. The lowest was 2.88. And the median was 5.90.


United Therapeutics  (FRA:UTH) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

United Therapeutics's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=462.10/43.65
=10.59

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of United Therapeutics was 11.59. The lowest was 2.88. And the median was 5.90.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


United Therapeutics Cyclically Adjusted Revenue per Share Related Terms


United Therapeutics Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for United Therapeutics's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

United Therapeutics Cyclically Adjusted Revenue per Share Chart

United Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 30.26 35.29 37.22 43.95 43.15

United Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.38 40.61 41.77 43.15 43.65

FRA:UTH vs VTRS, NBIX, ZTS: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, United Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


United Therapeutics Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, United Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where United Therapeutics's Cyclically Adjusted PS Ratio falls into.


FRA:UTH
82GF Score
United Therapeutics Corp FRA:UTH
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

United Therapeutics Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, United Therapeutics's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=14.322/330.2130*330.2130
=14.322

Current CPI (Mar. 2026) = 330.2130.

United Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 7.830 241.018 10.728
201609 7.872 241.428 10.767
201612 8.559 241.432 11.706
201703 7.547 243.801 10.222
201706 8.813 244.955 11.880
201709 8.476 246.819 11.340
201712 8.924 246.524 11.953
201803 7.190 249.554 9.514
201806 8.767 251.989 11.489
201809 8.038 252.439 10.514
201812 7.619 251.233 10.014
201903 7.343 254.202 9.539
201906 7.514 256.143 9.687
201909 8.286 256.759 10.656
201912 6.392 256.974 8.214
202003 7.312 258.115 9.354
202006 7.240 257.797 9.274
202009 7.236 260.280 9.180
202012 7.000 260.474 8.874
202103 6.863 264.877 8.556
202106 7.835 271.696 9.522
202109 7.941 274.310 9.559
202112 7.671 278.802 9.086
202203 8.793 287.504 10.099
202206 9.183 296.311 10.234
202209 10.701 296.808 11.905
202212 9.392 296.797 10.449
202303 9.545 301.836 10.442
202306 11.123 305.109 12.038
202309 11.489 307.789 12.326
202312 11.274 306.746 12.136
202403 12.545 312.332 13.263
202406 13.982 314.175 14.696
202409 13.941 315.301 14.600
202412 14.490 315.605 15.161
202503 15.120 319.799 15.612
202506 14.335 322.561 14.675
202509 14.401 324.800 14.641
202512 14.267 324.054 14.538
202603 14.322 330.213 14.322

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €43.65 mean?
United Therapeutics (FRA:UTH) has a Cyclically Adjusted Revenue per Share of €43.65 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on United Therapeutics and its competitors.
Is United Therapeutics' Cyclically Adjusted Revenue per Share too high?
United Therapeutics' current Cyclically Adjusted Revenue per Share is €43.65. Overall, United Therapeutics has a GF Score™ of 82/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does United Therapeutics' Cyclically Adjusted Revenue per Share compare to VTRS and NBIX?
United Therapeutics' Cyclically Adjusted Revenue per Share of €43.65 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on United Therapeutics and its competitors. United Therapeutics's current Cyclically Adjusted Revenue per Share is €43.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is United Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, United Therapeutics (FRA:UTH) is currently considered Significantly Overvalued. The stock's GF Value™ is €334.33, compared to a current price of €462.10 — trading 38.2% above its estimated fair value. The current Cyclically Adjusted Revenue per Share is €43.65. United Therapeutics' overall GF Score™ is 82/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For United Therapeutics (FRA:UTH), the current Cyclically Adjusted Revenue per Share is €43.65 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is United Therapeutics (FRA:UTH) Overvalued in 2026?

Based on GuruFocus' analysis, United Therapeutics stock appears to be overvalued. The current stock price of €462.10 is trading 38.2% above its estimated GF Value™ of €334.33. GuruFocus considers United Therapeutics to be Significantly Overvalued.

Key valuation signals for FRA:UTH:

  • Cyclically Adjusted Revenue per Share: €43.65
  • GF Value™: €334.33 vs. price of €462.10 (38.2% above fair value)
  • GF Score™: 82/100 with 3 warning signs

No single metric tells the full story. See the FRA:UTH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


United Therapeutics Business Description

Other Exchanges UTHR:USAU2TH34:Brazil
Address 1000 Spring Street, Silver Spring, MD, USA, 20910
United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.
82GF Score

Get the complete analysis for FRA:UTH

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€462.10
Price
€334.33
GF Value